Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BIOGEN INC. DL -,0005 (IDP.DU)

Dusseldorf - Dusseldorf Delayed Price. Currency in EUR
291.80+2.25 (+0.78%)
At close: 09:01PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close289.55
Open288.75
Bid291.80 x 0
Ask293.65 x 0
Day's Range287.30 - 293.60
52 Week Range174.68 - 308.00
Volume20
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateFeb 01, 2023 - Feb 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • The Wall Street Journal

    Second Time Might Be the Charm for Alzheimer’s Blockbuster

    Biogen had been a sinking ship following its Alzheimer’s flop, but positive results in September have changed the company’s trajectory.

  • The Wall Street Journal

    Biogen Names Christopher Viehbacher New CEO

    The veteran pharmaceutical executive takes charge after the failed launch of Biogen’s once-promising Alzheimer’s disease drug Aduhelm.

  • GlobeNewswire

    Biogen Names Christopher Viehbacher President and Chief Executive Officer

    Distinguished Industry Leader Brings Extensive International Experience in Large Pharmaceutical and Entrepreneurial Biotech Companies Christopher A. Viehbacher Christopher A. Viehbacher CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced that its Board of Directors has appointed Christopher A. Viehbacher as President and Chief Executive Officer and a member of the Board of Directors, effective November 14. Viehbacher succeeds Michel Vounatsos, who has l

Advertisement
Advertisement